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Abstract
Background: The worldwide outbreak of influenza A (H5N1) viruses among poultry species and
humans highlighted the need to develop efficacious and safe vaccines based on efficient and
scaleable production.
Results: White spot syndrome virus (WSSV) immediate-early promoter one (ie1) was shown to
be a stronger promoter for gene expression in insect cells compared with Cytomegalovirus
immediate-early (CMV) promoter in luciferase assays. In an attempt to improve expression
efficiency, a recombinant baculovirus was constructed expressing hemagglutinin (HA) of H5N1
influenza virus under the control of WSSV ie1 promoter. HA expression in SF9 cells increased
significantly with baculovirus under WSSV ie1 promoter, compared with CMV promoter based on
HA contents and hemagglutination activity. Further, immunization with baculovirus under WSSV
ie1 promoter in chickens elicited higher level anti-HA antibodies compared to CMV promoter, as
indicated in hemagglutination inhibition, virus neutralization and enzyme-linked immunosorbent
assays. By immunohistochemistry, strong HA antigen expression was observed in different chicken
organs with vaccination of WSSV ie1 promoter controlled baculovirus, confirming higher efficiency
in HA expression by WSSV ie1 promoter.
Conclusion: The production of H5 HA by baculovirus was enhanced with WSSV ie1 promoter,
especially compared with CMV promoter. This contributed to effective elicitation of HA-specific
antibody in vaccinated chickens. This study provides an alternative choice for baculovirus based
vaccine production.
Background
The spread of highly pathogenic avian influenza A
(H5N1) viruses from Asia to the Middle East, Europe, and
Africa poses the threat of an influenza pandemic. Vaccina-
tion of poultry is an effective measure to control virus
spread [1]. Current production of inactivated influenza
vaccine requires high-level biocontainment facilities and
large numbers of embryonated chicken eggs, while bacu-
lovirus surface displayed recombinant hemagglutinin
may be an attractive alternative to the effective influenza
vaccine [2-5].
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White spot syndrome virus (WSSV), a major pathogen in
shrimp, can infect a wide range of invertebrate tissues and
cells. WSSV genome has 9 repeated regions similar to
those of baculovirus, suggesting the potential to exploit
WSSV promoters in baculovirus and insect cell expression
system [6,7]. Baculovirus produces high yield of foreign
soluble protein in insect cells and mediates efficient trans-
duction of mammalian cells. Thus, it is widely used as a
vaccine production system [8]. WSSV ie1 promoter was
reported as one of the strongest promoters in insect cells
[9,10]. However, no documented report has compared
the activity of WSSV ie1 promoter with other promoters in
vaccine production. In this study recombinant baculovi-
ruses were constructed under WSSV ie1 promoter, in an
attempt to establish a novel platform for efficient antigen
expression. These recombinant baculoviruses were further
evaluated in the hemagglutinin production of H5N1
influenza virus.
The influenza virus HA glycoprotein has receptor-binding
activity and mediates viral-endosomal membrane fusion
during viral entry and serves as the primary target for neu-
tralizing antibodies [11,12]. HA protein from H5N1 influ-
enza virus expressed in baculovirus mediated by WSSV ie1
promoter can be displayed on baculovirus surface without
disrupting its authentic cleavage, hemagglutination activ-
ity and immunogenicity [13]. Besides, baculovirus pseu-
dotyped with the vesicular stomatitis virus glycoprotein
(VSV G) emerges as a promising gene-delivery vector by
virtue of its capability in transducing numerous mamma-
lian cells [14,15]. Coexpressed with VSV G in baculovirus,
the HA protein could be delivered into host cells to elicit
immune response in a long term. For the efficient HA
delivery to target cells, an active promoter is required in
both vertebrate and invertebrate species.
The current study compared WSSV ie1 promoter with
CMV promoter in the context of baculovirus vector for the
efficient expression of HA protein from H5N1 influenza
virus as a surface-displayed immunogen in SF9 (Spodop-
tera frugiperda) cells. Further studies on immunogenicity
were performed for these baculovirus vaccines under
WSSV ie1 promoter in chickens. The results demonstrated
that HA of H5N1 influenza virus could be more efficiently
produced by baculovirus with WSSV ie1 promoter, which
serves as a safe vaccine in chickens and provides effective
immune protection from avian influenza.
Results
WSSV ie1 promoter mediates efficient protein expression 
in SF9 cells
In order to investigate whether the relative strength of the
promoter was cell type dependent, a plasmid containing
WSSV iel promoter (phRL-ie1) for luciferase expression
was transfected into CEF and SF9 cells to test luciferase
activity, in comparison to CMV (phRL-CMV). Luciferase
activity, indicating intracellular luciferase quantity, was
presented in folds of the basic value set in the system.
Hence, a link was established between promoter activity
and luciferase activity. SV40 promoter was used as a con-
trol promoter in both insect and mammalian cells. Vero
cells were used to normalize transfection efficiency. CMV
promoter activity (mean 87 folds, SD 5.3) was much
weaker than the WSSV iel promoter (mean 1610 folds, SD
26.4) in SF9 cells. In CEF cells, the WSSV iel promoter
activity (mean 6195 folds, SD 156.8) was slightly less than
the CMV (mean 12715 folds, SD 258.8) (Fig 1). The data
indicated that the WSSV iel promoter activity was strong
in insect cells, in which CMV promoter activity was weak.
Furthermore, WSSV ie1 promoter was found to be active
in all of the vertebrate cells tested here, including human
TK-143b, monkey Marc145, Vero, porcine PK15 and carp
epithelioma papillosum (EPC) (data not shown). This
property of WSSV ie1 promoter renders it a promising
candidate for efficient protein expression in baculovirus
infected SF9 cells.
WSSV ie1 promoter stimulates strong H5 hemagglutinin 
expression in baculovirus
To further compare WSSV ie1 promoter with CMV pro-
moter in the efficiency of protein expression, four recom-
binant baculoviruses were constructed, termed as vAc-ie-
HA and vAc-CMV-HA expressing HA; vAc-G-ie-HA and
vAc-G-CMV-HA coexpressing VSV G protein with HA for
gene transduction [16,17] (Fig 2). To confirm the activity
of WSSV ie1 promoter in SF9 cells as shown in luciferase
test, SF9 cells were infected with the four recombinant
baculoviruses individually. The infected cells were fixed
and subjected to antibody staining 3 days postinfection.
3D4 and 8B6 are two different H5-specific monoclonal
antibodies used in these studies [18]. As shown in Fig 3A,
indirect fluorescence signals from HA protein were strong
and sharp by recombinant baculoviruses with WSSV ie1
promoter. HA expression was detected in cells infected
with CMV promoter-controlled baculoviruses though the
fluorescence signals were diffused and faded. For those
baculoviruses with VSV G cassette, the staining with anti-
VSVG antibody verified the successful coexpression of VSV
G protein and suggested the selected promoter has no
effect on the infection efficiency (Fig. 3A).
Baculovirus-expressed HA sustains hemagglutination
activity. The HA titer of baculoviruses under different pro-
moters was evaluated with the same number of virus par-
ticles. 25 μl of baculovirus at a titer of 1010 PFU/ml was
used in the standard hemagglutination assay. Data were
collected from 4 parallel assays. As shown in Figure 3B,
constructs under WSSV ie1 promoter gave a higher mean
hemagglutination titer of 1:256 (vAc-ie-HA) to 1:320
(vAc-G-ie-HA), while those under CMV were at a meanBMC Microbiology 2008, 8:238 http://www.biomedcentral.com/1471-2180/8/238
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titer of 1:44 (vAc-CMV-HA) to1:48 (vAc-G-CMV-HA) (p <
0.05). Coexpression of VSV G protein had no significant
effect on the hemagglutination result (p ≥ 0.359). Besides,
at a mean titer of 1:112, vAc-pol-HA, a HA-expressing con-
struct under baculovirus polyhedrin promoter, was
included in this hemagglutination test as a system control,
since it is widely used in recombinant baculoviruses for
HA production [8]. The HA titer of vAc-ie-HA was higher
than vAc-pol-HA at the same virus copies (p < 0.0001),
indicating its advantage in HA production.
To verify this result, recombinant virus copies and HA
contents were measured in a time course study during bac-
ulovirus infection. As shown in Fig. 3C, the temporal
kinetics of the growth curves for these viruses were similar
[13] among the three promoters studied here. However,
differences were found in HA production with the three
promoters (Fig. 3D). With WSSV ie1 promoter, the HA
content in virions was up to 6.6 ug/ml (SD 0.56) corre-
sponding to the virus titer of 109 PFU/ml at 96h post-
infection. The HA content of polyhedrin promoter was
5.05 ug/ml (SD 0.48) at the similar virus titer, while the
HA production of CMV promoter was around 2 ug/ml
(SD 0.40) at the same collection time. In ANOVA test, p
values for comparisons among three promoters at each
time point were less than 0.005 and the differences
between each two groups were considered as significant.
(For N tests, p < 0.005 is significant at the overall 0.05
level with Bonferroni adjustment.) Taken together, these
results indicated that WSSV ie1 promoter can induce more
abundant H5 hemagglutinin expression in baculovirus
with hemagglutination activity, in comparison to polyhe-
drin promoter, as well as CMV promoter.
Immunogenicity of H5 hemagglutinin expressed by WSSV 
ie1 promoter in chickens
The immunogenicity of baculovirus under WSSV ie1 pro-
moter or CMV promoter was subsequently investigated
through intramuscular (IM) or intranasal immunization
(IN) of 2-week-old chickens with purified live virions
without adjuvant. The live H5N1 vaccine (VNH5N1-PR8/
CDC-RG) was used as the positive control, while PBS vac-
cinated chickens served as negative controls. The same
H5N1 (VNH5N1-PR8/CDC-RG) strain was inactivated
with BEI (binary ethylenimine) [19] as another control.
The serology assays performed here were based on five dif-
ferent serum samples from five individual chickens in the
each group (95% confidence interval is between 8.72 and
35.02). To determine the neutralizing antibody level in
those chicken sera, HI tests were performed with H5N1
(VNH5N1-PR8/CDC-RG). As shown in Table 1, the WSSV
ie1-type baculoviruses elicit higher HI titer than CMV pro-
moter in serum samples. Coexpression of VSV G also con-
tributes to an increase in anti-HA antibody level with HI
activity. In addition, to confirm this result about the neu-
tralization activity, a standard micro-neutralization test
was performed with H5N1 (VNH5N1-PR8/CDC-RG) in
MDCK cells. The sera induced by WSSV ie1-controlled
Comparison of promoter activity of WSSV ie1 and CMV promoter in luciferase assays in different cell lines Figure 1
Comparison of promoter activity of WSSV ie1 and CMV promoter in luciferase assays in different cell lines. 
The relative luciferase activity was expressed as fold activity 24 h post-transfection, and the data were from three transfec-
tions. The transfections were performed with the reporter plasmid phRL with WSSV ie1, CMV and SV40 promoter individu-
ally. CEF: transfections in chicken embryo fibroblasts; SF9: transfections in SF9 cells. Vero: transfections in Vero cells. p. value is 
less than 0.005, when WSSV ie promoter was compared with CMV promoter in SF9 cells, evaluated in t-test.
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Schematic representation of the construction of variant baculoviruses in the study Figure 2
Schematic representation of the construction of variant baculoviruses in the study. The HA expression cassettes 
was inserted under different promoter individually. The desired VSV G expression cassettes was inserted under the polyhedrin 
promoter. ie: WSSV ie1 promoter; CMV: CMV promoter; pol: Polyhedrin promoter; G: VSV G protein; polyhedrin locus is 
based on pFast-1 baculovirus vector in Bac-Bac system.
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HA-displaying baculoviruses showed a higher neutraliza-
tion titer than those from CMV promoter, while coexpres-
sion of VSV G protein enhanced the neutralization titer in
samples of both WSSV ie1 and CMV promoters. Further,
serum samples were tested in ELISA. Serum samples from
the second collection were diluted at 100 fold in PBS and
tested for the anti-HA antibody level. For those samples
from intramuscular injection (Fig. 4A), at the same dosage
of virus inoculated, the chickens immunized with those
baculoviruses under WSSV ie1 promoter developed
higher antibody response than those under CMV pro-
moter (p < 0.05). Moreover, coexpression of VSV G pro-
tein contributed to an increase in anti-H5 antibody level
(p < 0.05) due to the transduction mediated by VSV G pro-
tein. In the lack of constant virus replication in vivo, anti-
body levels of these WSSV ie1 baculovirus immunized
chickens were relatively lower than those of live H5N1
(VNH5N1-PR8/CDC-RG) infected chickens (p  ≤ 0.09),
but they were higher than those of immunized chickens
with inactivated H5N1 (VNH5N1-PR8/CDC-RG) at the
same protein dosage (p < 0.05). For those intranasally
immunized chickens by baculovirus, lower IgG response
was detected compared with intramuscularly injected
chickens (Fig. 4B). Furthermore, cut-off value of this
ELISA was determined as 0.3 based on tests with healthy
new-born chicken serum. To further evaluate the HA-spe-
cific antibody level in sera, the dilution factor of each
serum sample was recorded (Table 1) at the value beyond
0.3 in ELISA. The data obtained in this method is consist-
ent to the results from other tests performed here. All of
these findings indicated that efficient production of HA by
Efficient production of activated HA protein of influenza virus by WSSV ie1 promoter in baculovirus Figure 3
Efficient production of activated HA protein of influenza virus by WSSV ie1 promoter in baculovirus. (A) 
Immunofluorescence assays with different recombinant baculovirus infected SF9 cells. Cells were fixed 3 days post-infection 
and subjected to antibody staining. 3D4 and 8B6 are H5-specific monoclonal antibodies. Anti-VSVG is anti-VSV G protein anti-
body. (B) Hemagglutination assays. Every 25 μl of baculovirus at a titer of 1010 PFU/ml was loaded into the standard hemagglu-
tination assay. Data were collected from 4 parallel assays. (C) One-step growth curves of baculoviruses under three different 
promoters in SF9 cells. Each data point represents the mean value of four individual infections. SF9 cells were infected by indi-
vidual viruses with a MOI of 0.5 PFU/cell. (D) HA contents of baculoviruses under three different promoters during infection. 
Data, shown in mean + SD, were collected from 4 parallel assays.
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WSSV ie1 promoter in baculovirus allowed it to be
exploited as a vaccine production platform.
Significant antigen expression in chicken tissue was 
induced by HA-VSV G coexpression constructs
To further study HA-transduction in immunized chickens
and detect antigen expression in tissue based on vaccina-
tion, immunohistochemistry of frozen tissue sections
from chickens was performed with an H5-specfic mono-
clonal antibody 2 weeks after the second vaccination.
Four chickens of each group were tested. Similar results
were found among 3 chickens in the group of vAc-G-ie-
HA by IM, 4 of vAc-G-ie-HA by IN, 3 of vAc-G-CMV-HA
by IM and 2 of vAc-G-CMV-HA by IN. In both of the two
promoter groups, signals were mainly observed in the
lung tissues (intranasal inoculation) and thymus tissues
(intramuscular inoculation). As shown in Fig 4C, in fro-
zen tissue sections from chickens inoculated with recom-
binant HA-expressing baculovirus under WSSV ie1
promoter (vAc-G-ie-HA), signals of HA expression
appeared intensive and distributed densely. In tissues
from chickens inoculated with recombinant baculovirus
vAc-G-CMV-HA, sporadic signals for HA expression were
observed. These results gave direct evidence of successful
protein transduction by VSV G-expressing baculoviruses.
In addition, the recombinant baculovirus under WSSV ie1
promoter was shown to bring strong antigen expression in
chicken tissues, which depends on its activity of HA
expression in both of insect and chicken cells.
Discussion
The recombinant baculoviruses under WSSV ie1 promoter
presented here, present advantages in HA production and
gene transduction, relying on its promoter efficiency in
both vertebrate and invertebrate species. In this study,
CMV promoter was used for major comparison because it
displayed activity in both mammalian and insect cells as
indicated in luciferase assays and it is widely used for pro-
tein expression and gene transduction in numerous cell
lines [20-22]. However, CMV promoter might be rela-
tively weak for protein expression in insect cells. There-
fore, WSSV ie1 promoter was also compared with
polyhedrin promoter from baculovirus in HA expression
in insect cells. The results confirmed the role of WSSV ie1
promoter as an efficient promoter for baculovirus medi-
ated protein expression. HA expressed in baculovirus
served as exogenous antigen to stimulate primary
immune response, while HA de novo expression in chicken
Table 1: Elicitation of influenza A virus HA specific antibody in chickens immunized with HA expressing recombinant baculovirus.
Inoculum Dose Route HI GMT (range) VN GMT (range) ELISA GMT (range)
1st Dose 2nd Dose 1st Dose 2nd Dose 1st Dose 2nd Dose
vAc-G-ie-HA 109 PFU IM 6.4
(4–8)
204.8a
(128–256)
32
(20–40)
192a
(160–320)
384
(320–640)
12288a
(10240–20480)
vAc-ie-HA 109 PFU IM 3.2
(2–4)
11.2b
(8–16)
8
(<10–10)
28b
(20–40)
224
(160–320)
5120b
(5120)
vAc-G-CMV-HA 109 PFU IM 2.4
(2–4)
76.8c
(64–128)
16
(10–20)
112c
(80–160)
288
(160–320)
9216c
(5120–10240)
vAc-CMV-HA 109 PFU IM 1.6
(<2–2)
4.8d
(4–8)
6
(<10–10)
13d
(<10–20)
192
(160–320)
2560d
(2560)
H5N1/PR8 Inactivated 6 ug IM 2
(2)
5.6
(4–8)
7
(<10–10)
22
(<10–40)
64
(40–80)
3072
(2560–5120)
H5N1/PR8 6 ug or 105 TCID50 IM 96
(32–128)
1024
(1024)
64
(40–80)
352
(160–640)
2560
(2560)
>20480
(20480)
PBS 100 ul IM 1
(<2)
1
(<2)
5
(<10)
5
(<10)
5
(<10)
5
(<10)
HI: hemagglutination inhibition titer of serum from immunized chickens. VN: virus microneutralization titer of serum from immunized chickens. 
GMT: geometric mean titer. GMT is calculated based on 5 different sera from 5 different chickens in each groups. For titers <2 in HI, 1 was used to 
calculate the GMT. A GMT of 1 was considered negative. For titer <10 in VN and ELISA, 5 was used to calculate the GMT. A GMT of 5 was 
considered negative. 1st Dose: serum samples collected at 2 weeks from the first inoculation. 2nd Dose: serum samples collected at 2 weeks from 
the second inoculation. IM: intramuscular.
a-d p < 0.05. Values denoted by different letters are statistically different from each other in the same comparison, as analyzed in ANOVA test (not 
adjusted).BMC Microbiology 2008, 8:238 http://www.biomedcentral.com/1471-2180/8/238
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tissue will contribute to the trigger of new HA-antibody
production for further protection in a long run [18,20].
For gene transduction, although CMV promoter is
stronger in chicken cells than WSSV ie1 promoter, as indi-
cated in luciferase assays, such advantage could be offset
by the stronger HA expression on viral surface with WSSV
ie1 promoter, which eventually leads to enhanced HA-
specific immune response in chickens [23].
To further verify those advantages brought by WSSV ie1
promoter in vaccine production, the immunogenicity of
these baculovirus-based immunogens was studied with
chickens. In the comparison of different promoters in the
same type of baculovirus construct, vaccine dose was
based on virus copies rather than protein contents in
order to differentiate the HA production efficiency by dif-
ferent promoters with the same amount of baculovirus
copies (109 PFU) [8]. As shown here, at the same dosage
of baculovirus, constructs with WSSV ie1 promoter elic-
ited better immune response than CMV promoter, con-
firming the higher HA expression level by WSSV ie1
promoter. Meanwhile, when the comparison was per-
formed between baculovirus and attenuated H5N1 influ-
Immunogenicity of HA-expressing baculoviruses Figure 4
Immunogenicity of HA-expressing baculoviruses. (A,) ELISA antibody levels in chicken induced by various immunogens 
via intramuscular infection. (B) ELISA antibody levels induced by various immunogens via intranasal inoculation. Each group (n = 
5) of chickens were immunized with different vaccines at the same dose of virus particles or protein contents. Two weeks after 
the second vaccination, serum samples from individual chickens in each group were tested by ELISA with purified virion of 
H5N1 (VNH5N1-PR8/CDC-RG) as antigen. The results are expressed as the absorbance of 1:100 diluted individual sera at 
OD490. (C) Immunohistochemistry with frozen tissue sections from vaccinated chickens. Thymus was collected from intra-
muscularly immunized chickens and lung was collected from intranasally immunized chickens. PBS: tissues from control chick-
ens with PBS.
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enza virus, dosage was based on HA contents (6 ug) due
to differences in viral property.
As the direct evidence for gene transduction, HA antigen
expression in tissues was revealed in IHC assays. The
results were repeatedly observed in most chickens from
each group and considered to be significant. For intrana-
sal inoculation, lung is the major organ to directly contact
immunogen upon vaccination, where VSV G mediates
virus entry and HA expresses with its individual promoter.
Also, as the major organ involved in immunity of avian
species, thymus supports exogenous antigen expression
[24-26]. Therefore, for intramuscular injections, most of
HA expression was detected in chicken thymus.
Although baculovirus-expressed hemagglutinin influenza
vaccines have been widely used and well characterized in
different ways and under variant vector designs [5,8,27-
29], innovative methods are under investigation for more
efficient HA production at a higher hemagglutination
titer. WSSV ie1 promoter supports the abundant produc-
tion of HA in baculovirus system, as compared with other
promoters tested here. This allows it to induce higher level
of specific antibody response in immunized poultries at
the same number of baculovirus copies. In addition, com-
pared with inactivated H5 influenza virus vaccines at the
same dose of HA protein (p < 0.05), data shown here indi-
cates that WSSV ie1 promoter-mediated baculovirus vac-
cine could present better immunogenicity without
biosafety concerns in vaccine preparation [30]. This also
suggests that there could be some other properties of
WSSV ie1-controlled baculovirus contributing to better
immunogenicity. One possibility is that the surface-dis-
played HA in baculovirus sustains its natural conforma-
tion upon vaccination due to the obviation of the
inactivation process in the baculovirus-type vaccine pro-
duction [8]. Future studies will focus to identify whether
other properties of WSSV ie1 promoter support strong
immunogenicity. Taken together, our studies provide an
alternative choice for the efficient production of surface-
displayed HA with baculovirus. Its vaccine potential was
primarily studied in chickens, which might throw light on
its promising trials in humans.
Conclusion
With WSSV ie1 promoter, the recombinant baculovirus
provided an efficient and expeditious method in vaccine
production, compared with traditional means. WSSV ie1
promoter-mediated baculovirus conferred better immu-
nogenicity in chickens upon vaccination in the light of the
efficient HA expression in both insect and chicken cells.
This study fully characterized the capacity of baculovirus
featuring WSSV ie1 promoter in antigen production and
immune response elicitation in chickens, suggesting it
could be a promising choice as an efficient vaccine pro-
duction system.
Methods
Viruses and cells
VNH5N1-PR8/CDC-RG obtained from Center for Disease
Control (USA) is a non-pathogenic H5N1 influenza virus.
PR8 strained-based reassortant virus comprises of the HA
and NA gene of AIV H5N1 virus infecting human in Viet-
nam (A/Vietnam/1203/04). The virus was grown in the
allantoic cavities of 10-day-old embryonated eggs
(Chew's Poultry Farm, Singapore).
Madin-Darby canine kidney (MDCK) cells and African
green monkey cell line (Vero) were obtained from Ameri-
can Type Culture Collection (ATCC) and grown in DMEM
containing 10% FBS at 37°C with 5% CO2. Spodoptera fru-
giperda pupal ovarian (SF9) cells (Invitrogen) were grown
at 28°C in serum-free medium Sf-900 II SFM (GIBCO
BRL) supplemented with 100 μg/ml gentamycin and
transfected with Effectene transfection reagent (Qiagen).
Primary chicken embryo fibroblasts (CEF, prepared from
specific-pathogen-free chicken embryo, Chew's Poultry
Farm, Singapore) were cultured in RPMI 1640 (GIBCO
BRL) medium supplemented with 10% fetal bovine
serum and 100 μg/ml penicillin and 100 μg/ml strepto-
mycin at 37°C under a 5% CO2 atmosphere.
Luciferase activity assay
Renilla luciferase activity was measured with the Dual-
Luciferase Reporter Assay System (Promega, Madison,
WI) according to the protocol (Technical Manual,
#TM040) using a Luminometer (Berthold, Lumat LB
9507, ITS Science & Medical PTE LTD) [31]. DNA was iso-
lated from WSSV-infected shrimps using DNeasy tissue kit
(Qiagen). Luciferase reporter plasmids were constructed
by inserting WSSV ie1 promoter into KpnI-Hind III sites of
phRL vector. Vector pRL-SV40 and pRL-CMV were pro-
vided in the kit. Cells were lysed in 1 × lysis buffer (50 μl/
well) for 15 min at room temperature and each cell lysate
was added into the luminometer tube containing 100 μl
of assay reagent. The mixture was mixed quickly by flick-
ing for 2 s, and placed in the luminometer for 10 s meas-
urement. Transfection efficiency was normalized using
pRL-SV40 in Vero cells, in which SV40 promoter drives
the firefly luciferase reporter gene. Data (mean + SD) were
collected from triplicate assays of three independent
transfections.
Construction of recombinant baculoviruses
For the generation of the recombinant baculovirus vec-
tors, as mentioned before [13], AcMNPV polyhedrin pro-
moter-controlled vesicular stomatitis virus glycoprotein
(VSV G) [17] expression cassette and WSSV ie1 promoter
or CMV promoter-controlled HA expression cassette (Fig-
ure 1) were inserted into the shuttle vector pFastBac1 and
integrated into the baculovirus genome within
DH10BAC™ according to the protocol of Bac-To-Bac sys-
tem (Invitrogen). HA gene in our study was amplifiedBMC Microbiology 2008, 8:238 http://www.biomedcentral.com/1471-2180/8/238
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from a Vietnam strain (A/Vietnam/1203/04/H5N1) with
the multibasic HA cleavage site in a standard PCR method
(94°C 20 sec, 55°C 30 sec and 72°C 2 min for 30 cycles).
CMV-HA cassette was amplified with a primer set of 5'
ACGCTACGTATAGTTATTAATAGTAATCAA 3' and
5'ACGTGCGGCCGCTTAAATGCAAATTCTGCATTGTAAC
GATC3' from vector pCMV-EGFP (BD clontech) with HA
gene. CMV promoter in the vector is Human cytomegalo-
virus (CMV) immediate early promoter without intron.
The CMV-HA cassette was inserted into pFastBac1 at the
SnabI-NotI site. HA was also inserted into pFastBac1 vec-
tor with polyhedrin promoter at the NotI-SalI site to gen-
erate vAc-pol-HA recombinant baculovirus.
Recombinant baculovirus purification
Infected SF9 cells with individual recombinant baculovi-
ruses were harvested at 96 h postinfection and subjected
to freeze-thaw cycles for cell lysis. The cell lysate was
spinned at 1000 g for 5 minutes to remove cell debris.
From the supernatant, the virus was purified by sucrose
gradient ultracentrifugation following standard protocols
[8] and the purity was determined by SDS-PAGE. Virus
titer was determined in standard plaque assays with SF9
cells according to baculovirus construction protocol (Inv-
itrogen, No.10359). Hemagglutinin contents in purified
virions were estimated by densitometric analysis of
stained gels following electrophoresis with Quantity One
software (Bio-Rad).
All of the baculoviruses were used without inactivation.
As a control of protein vaccine, H5N1 (VNH5N1-PR8/
CDC-RG) strain was inactivated with 0.3 M BEI (binary
ethylenimine) incubated at 37°C overnight, according to
the previous protocol [19].
Animal experiments
14-day-old chickens (Chew's Poultry Farm, Singapore)
received two doses of vaccines or PBS at intervals of 14
days by intramuscular injection or intranasal inoculation.
5 chickens were in each group. Each chicken was vacci-
nated with purified live baculoviruses without adjuvant at
the dose of 109 PFU based on virus copies (100 ul, 1010
PFU/ml), or with influenza virus without adjuvant at the
dose of 6 ug based on HA content or 105 TCID50 based on
infectivity. The sera were collected two weeks after each
vaccination for evaluation. Chickens were killed for dis-
section two weeks after the second vaccination.
Approval for the animal experiments was obtained from
Institutional Animal Care and Use Committee in Temasek
Life Sciences Laboratory, Singapore (the approved project
number TLL-07-007).
Serological assays
To inactivate non-specific inhibitors, chicken sera were
treated with receptor destroying enzyme (RDE, Sigma) by
incubation at 56°C for 30 min. Hemagglutination inhibi-
tion (HI) tests were carried out in microtitre plates with
1% suspension of chicken red blood cells. For neutraliza-
tion tests, 2 × 104/ml of MDCK cells were allowed to grow
to 70% – 90% of confluence. Allantoic fluids with
H5N1(VNH5N1-PR8/CDC-RG), using a series of dilu-
tions factors from 10-1 to10-8, were tested for TCID50.
Using Reed and Muench mathematical technique., the
infectivity titer was expressed as TCID50/100 μl and the
viruses (VNH5N1-PR8/CDC-RG) were diluted to having
100 TCID50 in 50 μl. After which, 100 TCID50viruses were
incubated with chicken serum for 1 h at 37°C and inocu-
lated into MDCK cells. The cells were then incubated at
37°C and CPE was observed at 96 h post-infection.
Besides, a cell-based ELISA were performed to determine
neutralization titer according to standard procedures
[32,33]. Guinea pigs were immunized with a live non-
pathogenic virus (VNH5N1-PR8/CDC-RG) at 6 ug of HA
contents and bled after two injections. The guinea pig IgG
was purified from serum using protein A affinity column
(Sigma, USA) in accordance with manufacturer's instruc-
tions. Enzyme-linked immunosorbent assays (ELISA)
were performed by antigen-capture methods with purified
anti-H5N1 IgG from guinea pig (150 ng/well) as captur-
ing antibody. The plate was then incubated with purified
virus (VNH5N1-PR8/CDC-RG) as antigen. The chicken
serum samples were added and anti-chicken IgG second-
ary antibody HRP (Sigma, 1:3000) was used to develop
signals with OPD substrate (Sigma, 1 tablet in 20 ml
water).
Immunofluorescence assays
SF9 cells were infected with HA-expressing baculovirus.
They were fixed at 3 days post-infection with 100 μl of
absolute ethanol for 10 minutes at room temperature.
Cells in 96-well plates were then washed 3 times with PBS,
pH 7.4. Subsequently, the fixed cells were incubated with
50 μl of anti-H5 [18] or anti-VSVG monoclonal antibody
(Sigma) for 1 hr at 37°C. After 3 washings, the antigens
were incubated with fluorescein isothiocyanate (FITC) –
conjugated anti-mouse Ig (1:100 DAKO, Denmark) for 1
h at 37°C. The cells were observed under fluorescence
microscope.
Immunohistochemistry
Chickens were dissected after 2 weeks from the second
vaccination and a series of organ tissues were collected,
including brain, kidney, liver, lung and spleen. They were
in the form of frozen sections. Commercially available
immunoperoxidase staining system (Dako Cytomation
EnVision + System-HRP (AEC)) was used for these speci-
mens according to instructions in the kit. This is a two-
step staining technique. to recognize bound antibodies.
based on a horseradish peroxidase labeled polymer which
is conjugated with secondary antibodies.BMC Microbiology 2008, 8:238 http://www.biomedcentral.com/1471-2180/8/238
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Statistical analysis
Welch's t test, which is the two-sample t-test that does not
assume equal variances between groups, was performed
to determine the level of significance in the difference
between means of two groups (GraphPad, Software). One
way ANOVA was performed by using ANOVA test calcula-
tor (Danielsoper, Software) online and the level of signif-
icance of difference in multiple comparison was
determined according to Bonferroni adjustment (α =
0.05) for multiple comparisons if applicable. 95% confi-
dence interval was determined using survey calculator
online (Creative research systems).
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